
Sarcomatrix Therapeutics to Present Advances in Muscle Disease Drug Development at 2025 BIO CEO & Investor Conference
Company Prepares for Phase 1 Clinical Trials of Lead Candidate S-969 in 2025 RENO, NV, UNITED STATES, February 7, 2025 /EINPresswire.com/ -- Sarcomatrix Therapeutics Corp., a clinical-stage biotechnology company focused on revolutionizing …